5-alpha-reductase deficiency history and symptoms: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{5-alpha-reductase deficiency}} {{CMG}} ==Overview== ==References== {{reflist|2}} {{WH}} {{WS}} Category:Disease [[Category:Endocrinology and Metabolic Disease]...")
 
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 3: Line 3:
{{CMG}}
{{CMG}}
==Overview==
==Overview==
==History and Symptoms==
The condition affects only males (i.e. those with a [[Y chromosome]]) because DHT has no known role in female development.
Individuals with 5-ARD can have normal male external genitalia, [[ambiguous genitalia]], or normal female genitalia. They are born with [[male]] [[gonad]]s, including [[testicles]] and [[Wolffian structures]], but usually appear to have [[female]] [[primary sex characteristic]]s. Consequently they are often raised as girls and develop a female [[gender identity]]. Individuals with obvious [[virilisation|undervirilisation]] at birth, eg. hypospadia, micropenis or complete [[ambiguous genitalia]] are currently raised as boys.
In individuals with feminised or ambiguous genitalia, there is a tendency towards an enlarged [[clitoris]], or [[micropenis|microphallus]], and the [[urethra]] may attach to the phallus. This structure may be capable of erections as well as ejaculations. Individuals with 5-ARD are generally capable of producing viable [[sperm]], however [[artificial insemination]] techniques or [[in-vitro fertilisation]] are necessary.
At [[puberty]], individuals often have primary [[amenorrhoea]], and may experience [[virilisation]]. This may include descending of the testes, [[hirsuitism]] and deepening of the voice. In adulthood, individuals do not experience male-pattern baldness.<ref name="Gpnotebook">{{GPnotebook|852492298}}</ref> As DHT is a far more potent androgen than testosterone alone, virilisation in those lacking DHT may be absent or reduced compared to males with functional 5-alpha reductase. It is hypothesized that rising testosterone levels at the start of puberty (around age twelve) are able to generate sufficient levels of DHT by either the action of 5-alpha-reductase type 1 (active in the adult liver, non-genital skin and some brain areas) or through the expression of low levels of 5-alpha-reductase type 2 in the testes.
==References==
==References==
{{reflist|2}}
{{reflist|2}}
Line 8: Line 16:
{{WS}}
{{WS}}
[[Category:Disease]]
[[Category:Disease]]
[[Category:Endocrinology and Metabolic Disease]]
[[Category:Endocrinology]]
[[Category:Genetic disorders]]
[[Category:Genetic disorders]]

Latest revision as of 19:51, 19 September 2012

5-alpha-reductase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 5-alpha-reductase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Molecular Genetic Studies

Genotyping

Pelvic X Ray

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

5-alpha-reductase deficiency history and symptoms On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 5-alpha-reductase deficiency history and symptoms

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 5-alpha-reductase deficiency history and symptoms

CDC on 5-alpha-reductase deficiency history and symptoms

5-alpha-reductase deficiency history and symptoms in the news

Blogs on 5-alpha-reductase deficiency history and symptoms

Directions to Hospitals Treating 5-alpha-reductase deficiency

Risk calculators and risk factors for 5-alpha-reductase deficiency history and symptoms

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

History and Symptoms

The condition affects only males (i.e. those with a Y chromosome) because DHT has no known role in female development. Individuals with 5-ARD can have normal male external genitalia, ambiguous genitalia, or normal female genitalia. They are born with male gonads, including testicles and Wolffian structures, but usually appear to have female primary sex characteristics. Consequently they are often raised as girls and develop a female gender identity. Individuals with obvious undervirilisation at birth, eg. hypospadia, micropenis or complete ambiguous genitalia are currently raised as boys.

In individuals with feminised or ambiguous genitalia, there is a tendency towards an enlarged clitoris, or microphallus, and the urethra may attach to the phallus. This structure may be capable of erections as well as ejaculations. Individuals with 5-ARD are generally capable of producing viable sperm, however artificial insemination techniques or in-vitro fertilisation are necessary.

At puberty, individuals often have primary amenorrhoea, and may experience virilisation. This may include descending of the testes, hirsuitism and deepening of the voice. In adulthood, individuals do not experience male-pattern baldness.[1] As DHT is a far more potent androgen than testosterone alone, virilisation in those lacking DHT may be absent or reduced compared to males with functional 5-alpha reductase. It is hypothesized that rising testosterone levels at the start of puberty (around age twelve) are able to generate sufficient levels of DHT by either the action of 5-alpha-reductase type 1 (active in the adult liver, non-genital skin and some brain areas) or through the expression of low levels of 5-alpha-reductase type 2 in the testes.

References

Template:WH Template:WS